Logo

Apis Assay Technologies Breast Cancer Subtyping Kit

Sep 09, 2022

The UK-based company Apis Assay Technologies is launching its Breast Cancer Subtyping Kit as an in vitro diagnostic in the UK and for research use only in other geographies. The RNA-based diagnostic workflow can be used to detect mRNA expression of standard biomarkers (ER, PR, HER2, Ki67) and novel proliferative biomarkers from pre-operative core-needle biopsy or resected FFPE breast tumor tissue. The assay addresses several unmet needs in current practice, including a faster HER2 result turnaround without the need for reflex testing when the IHC result is unclear; higher accuracy of the Ki67 proliferation measurement; and significantly reduced time for results interpretation, the company said. The assay will also be accompanied by validated software for automatic results interpretation, Apis said.

Breaking News
The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.